期刊
ACG CASE REPORTS JOURNAL
卷 4, 期 -, 页码 -出版社
AMER COLL GASTROENTEROLOGY
DOI: 10.14309/crj.2017.57
关键词
-
Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, however, upper gastrointestinal events are rarely reported. We present a case of nivolumab-associated esophagitis and gastritis that has yet to be reported in the published literature.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据